

All cancer sites




Time-to-first chemotherapy treatment



Australia

New South Wales

*Victoria



Canada

Ontario

Alberta


British Columbia

*Prince Edward Island

Nova Scotia

*Manitoba

*Saskatchewan



Norway

*Norway




UK

England


Northern Ireland

*Wales

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Oesophageal cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

Victoria



Canada

Ontario


Alberta

Nova Scotia

British Columbia

Saskatchewan

Manitoba



Norway

Norway




UK

England


Wales

Northern Ireland

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Stomach cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

Victoria



Canada

Ontario


British Columbia

Alberta

Manitoba

Nova Scotia

Saskatchewan



Norway

Norway




UK

England


Wales

Northern Ireland

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Colon cancer


Time-to-first chemotherapy treatment



Australia

*Victoria

New South Wales



Canada

Ontario

British Columbia


*Alberta

Prince Edward Island

Manitoba

Nova Scotia

Saskatchewan



Norway

*Norway




UK

England


Northern Ireland

*Wales

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Rectal cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

*Victoria



Canada

Ontario

Alberta


British Columbia

*Manitoba

Nova Scotia

Prince Edward Island

Saskatchewan



Norway

*Norway




UK

England


*Wales

Scotland

Northern Ireland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Liver cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

*Victoria



Canada

Saskatchewan

Alberta

Nova Scotia

Ontario


British Columbia

*Manitoba



Norway

*Norway




UK

Northern Ireland


England

*Wales

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Pancreatic cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

Victoria



Canada

Prince Edward Island

British Columbia


Ontario

Alberta

Saskatchewan

Manitoba

Nova Scotia



Norway

Norway




UK

England


Northern Ireland

Wales

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.


Lung cancer

Time-to-first chemotherapy treatment




Australia

Victoria
New South Wales



Canada

Prince Edward Island
Alberta
Ontario
Nova Scotia
British Columbia
Saskatchewan
Manitoba




Norway

Norway




UK

England
Northern Ireland
Wales
Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.
Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Ovarian cancer


Time-to-first chemotherapy treatment



Australia

New South Wales

Victoria



Canada

British Columbia


Alberta

Nova Scotia

Ontario

Manitoba

*Saskatchewan



Norway

Norway




UK

England


Northern Ireland

Wales

Scotland



Time-to-first chemotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.